Speaking at AAPS PharmSci 360, Dr Stephanie Johnson, a principal formulation scientist at Pfizer, details how platform formulations save time before commitment, shift risk downstream, and what AI tools need to earn trust.
|Podcasts|August 18, 2021
Developing Cost-effective, Accelerated Downstream Processes
Author(s)Astrea Bioseparations
Astrea Bioseparations joins Biopharm International for a discussion about the evolving challenges of downstream processing for advanced therapies, and what the future might hold. We talk about the company’s evolution over the last three decades, including the Discover. Develop. Deliver. approach to customer alignment. The latest industry trends are reviewed, along with considerations to keep in mind during the selection of off the shelf or customized downstream solutions.
Related to this article
Phase 1b data at ESMO 2026 show the TCR-based T-cell engager produced durable responses in PRAME-high melanoma, with 91% of patients alive at one year in the recommended dose range.
In two small phase 1b trials, the half-life-extended bispecific antibody improved skin disease and reduced airway inflammation. Aclaris will move next into a Phase 2b trial in eosinophilic esophagitis.
Risvutatug rezetecan extended median progression-free survival to 5.5 months vs 1.4 months with chemotherapy in pretreated osteosarcoma.
Izalontamab brengitecan extended median progression-free survival to 11.1 months vs 5.7 months with chemotherapy after EGFR TKI failure.
Merck and Kelun’s sac-TMT extends overall survival in pretreated endometrial cancer, Bristol Myers Squibb reports interim data and a patient death in its phase 1 CAR-T trial in multiple sclerosis, and BioNTech and DualityBio’s HER2 ADC meets its phase 3 goal but with limited expected benefit.
This year's PharmSci 360 will close with a plenary on fixing drug development economics given by Averin's Dr Berry.
Dr Karunakar Sukuru of Catalent explains how lipid-based softgels address physiological barriers to oral peptide delivery as approvals increase.
Trending on BioPharm International
1
Merck and Kelun’s Sac-TMT Extends Survival by Nearly 7 Months in Pretreated Endometrial Cancer
2
BMS Reports Death in Phase 1 Zolacabtagene Autoleucel MS Study
3
The BioPharm Brief: Survival Gains, a Modest ADC Win, and CAR-T in Multiple Sclerosis
4
BioNTech’s HER2 ADC Hits Phase 3 Goal, but Companies See Limited Benefit
5